Encouraging Q2 21; but keep a close eye on COVID-19 situation
21/07/21 -"Novartis reported promising Q2 21 results, driven by a combination of improving pandemic situation and ‘softer comps’, i.e. reversal of forward buying in Q2 20. Most importantly, some momentum ..."
Pages
65
Language
English
Published on
21/07/21
You may also be interested by these reports :
03/11/25
BioNTech reported mixed Q3 results. Sales significantly exceeded market expectations, but the operating loss was higher than anticipated. The 2025 ...
31/10/25
Novo has locked horns with Pfizer by proposing to acquire obesity-focused Metsera, after Pfizer had made an offer in September 2025. Metsera’s ...
30/10/25
While Q3 sales fell marginally short of the street’s expectations, a healthily growing high-margin Biosimilars segment led to the 2025 profitability ...
29/10/25
The Q3 results exceeded expectations, driven by strong growth in the HIV, respiratory, immunology, oncology, and vaccines portfolio. Consequently, ...